Skip to content

Asarina Pharma AB (publ) releases Year-End Report 2022

(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone for Tourette Syndrome, on schedule, completing Last Patient Last Visit on February 1, less than 12 months after commencement. The patient dropout rate remained unexpectedly low throughout the study. Results continue to be expected at the end of March 2023.


  • Operating costs (MSEK 6.7) well under control 
  • Cash reserves at year-end (MSEK 13.6) enough to finance completion of Tourette study 
  • Strong balance sheet due to conversion of loan in May 2022


Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of 28 patients were enrolled. The last patient was randomized on October 14.

Extensive preclinical study published: on 6 October Asarina Pharma announced the publication of a comprehensive new preclinical study in the Neurobiology of Stress, the fourth in a series of four. Results increase the Translatability of Asarina Pharma’s data and provide further evidence for pursuing further clinical tests and an initial clinical trial in OCD.

Last Patient Last Visit: On February 1, 2023, following the reporting period, Last Patient Last Visit was reported in our Phase IIa Tourette study. The dropout rate remained unexpectedly low (two of the 28 patients dropped out.)

Topline results for the Study remain expected to be released at the end of March 2023.


CEO Peter Nordkild: “An overview of developments in the Tourette market and competitor landscape in 2022 confirms two major trends – its growing prevalence, backed up by a substantial US CDC Report – and the continuing unmet need for safer treatments. These are still early days for Sepranolone in Tourette. Nevertheless, we are keenly aware of just how unique its safety profile is, and how much that could set Sepranolone apart in a market such as Tourette. We look forward to releasing our topline results and further exploring the data.”

Read the full CEO Statement here: